Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Logo BenzingaBenzinga
2023-03-31 14:00:00  • 3 mins

Scribe Therapeutics Inc., a molecular engineering company enabling the creation of genetic medicines through its CRISPR by Design approach to genetic modification, today announced it will participate in the upcoming Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days, taking place from Monday, April 3 to Tuesday, April 4, 2023 in New York, NY.

Scribe's CEO Benjamin Oakes, PhD, is scheduled to join the private company panel at 1:00 PM EST on Monday, April 3 at the Lotte New York Palace.

About Scribe Therapeutics

Scribe Therapeutics is a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe engineers bacterial immune systems into genetic medicines through its CRISPR by Design approach leveraging all previous iterations of CRISPR technology. The company is backed by leading individual and institutional investors including Andreessen Horowitz, Avoro Ventures and Avoro Capital Advisors, OrbiMed Advisors, Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, and Menlo Ventures. To learn more about Scribe's mission to engineer the future of genetic medicine, visit

Continue read on

In this free webinar, learn how to accelerate clinical trials by addressing the challenges of sample collection and sample accuracy. Attendees will learn...
Logo BenzingaBenzinga
2023-06-08 12:30:00  • 2 mins
Most smaller biotech companies would love to follow in the footsteps of Vertex Pharmaceuticals (NASDAQ: VRTX). The company is the global leader in cystic...
- First CRISPR gene-editing filings to be accepted for review by FDA - - FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review...
Logo BenzingaBenzinga
2023-06-08 23:23:00  • 2 mins
Atara Biotherapeutics, Inc. ATRA, a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop...
Logo BenzingaBenzinga
2023-06-07 20:01:00  • 2 mins
New product bolsters growing single cell portfolio Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions,...
Logo BenzingaBenzinga
2023-06-08 12:07:00  • 1 min
The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify...
Logo BenzingaBenzinga
2023-06-08 18:00:42  • 1 min
National Cerebral and Cardiovascular Center (NCVC) in Japan and NTT Research MEI Lab Target Medical and Healthcare Applications NTT Research, Inc., (NTTR) a...
Logo BenzingaBenzinga
2023-06-08 12:07:00  • 1 min
Vivos Therapeutics VVOS reported its Q1 earnings results on Thursday, June 8, 2023 at 04:05 PM. Here's what investors need to know about the announcement....
Logo BenzingaBenzinga
2023-06-08 20:15:41  • 1 min
The company's third commercial CAR T manufacturing facility in the U.S. further extends Bristol Myers Squibb's leadership in cell therapy Bristol Myers...
Logo BenzingaBenzinga
2023-06-08 20:16:00  • 2 mins
The Stallergenes Greer Foundation aims to create healthier futures for all. The Foundation, under the aegis of the Fondation de France, is philanthropically...
Logo BenzingaBenzinga
2023-06-08 08:00:00  • 1 min
The funding follows a $55 million round the company raised nearly two years ago.
Logo The Business JournalsThe Business Journals
2023-06-08 10:55:48  • 1 min
Acrobat Genomics, NanoString Technologies, Inc. NSTG, and the Illumina Accelerator announced today their collaboration with Stanford Medicine to discover new...
Logo BenzingaBenzinga
2023-06-08 11:01:00  • 1 min
Pfizer Inc PFE, BioNTech SE BNTX, and Moderna Inc MRNA were named in lawsuits by Promosome accusing their COVID-19 vaccines of infringing a patent related to...
Logo BenzingaBenzinga
2023-06-07 12:51:03  • 1 min
By Chloe Harcombe and Esme Ashcroft BBC News A laboratory has opened to explore how innovations like wearable technology and artificial intelligence (AI) can...
2023-06-08 14:21:43  • 1 min
Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd ESALY/ Biogen...
Logo BenzingaBenzinga
2023-06-08 15:27:15  • 1 min
Robert C. Lyons, president and chief executive officer, GATX Corporation GATX, will participate in a fireside chat at the 2023 Wells Fargo Industrials...
Logo BenzingaBenzinga
2023-06-08 17:49:00  • 2 mins
The National Health IT Collaborative for the Underserved (NHIT), the first and oldest national non-profit focused on equitable access to health technology...
Logo BenzingaBenzinga
2023-06-09 01:15:00  • 1 min
SAR'579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46CD16 NK cell engager from a joint research collaboration between Innate Pharma and...
Logo BenzingaBenzinga
2023-06-08 05:00:00  • 2 mins
Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and...
Logo BenzingaBenzinga
2023-06-02 18:34:00  • 1 min
Exact Sciences bought Genomic Health four years ago for nearly $3 billion. Now it's shedding some of the office space acquired as part of that deal.